Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- OPINION／Getting to the Honne of the Matter: Part Two Turning Frustration into Success
September 22, 2008
- Chugai Relaxes Post-Marketing Safety Measures for Avastin
September 22, 2008
- R&D NEWS IN BRIEF
September 22, 2008
- More PE Specialists Needed to Enhance PM Safety Measures: Mr Kokan
September 22, 2008
- SEMINAR／New Drugs for Diabetic Nephropathy Needed: JHSF Seminar
September 22, 2008
- GENERICS NEWS IN BRIEF
September 22, 2008
- NovoRapid 30 Mix Decreases HbA1c without Increasing Incidence of Serious Hypoglycemic Events
September 22, 2008
- BUSINESS NEWS IN BRIEF
September 22, 2008
- Saxagliptin Effective in Combination with Other Oral Antidiabetic Agents
September 22, 2008
- Pramipexole Improves Symptoms Associated with RLS: BI
September 15, 2008
- Greater Incentives Necessary to Further Increase Use of Generics: Dr Muto
September 15, 2008
- Novartis Has 8 NDAs Pending: Most Ever
September 15, 2008
- A Case of Diagnosis and Treatment of Effort Angina in Japan
September 15, 2008
- Jiho-Organized Industry Tour Group Visits Leiden Bio Science Park
September 15, 2008
- Korosho to Verify Quality of Generics of 10 APIs
September 15, 2008
- Loxonin Tape Leads Rep Track Survey Ranking in July
September 15, 2008
- AIDS Drugs Effective against Resistant Virus Needed
September 15, 2008
- Yamato Will Not Be Able to Be Profitable with Generics Alone: Mr Kumakura
September 15, 2008
- Publicity on Effective Migraine Treatment Needed: GSK Seminar
September 15, 2008
- Will Distribution Practices Be Improved? Part 1
September 15, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…